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Atherosclerosis is still a great burden on human health and scientific achievements of the past
30 years have definitively proven the inflammatory causes of the disease (1, 2) highlighted by the
results of the CANTOS trial (3). Canakinumab inhibition of interleukin-1 (IL1)-beta has been
demonstrated to provide protection against cardiovascular (CV) risk irrespective of lipid levels in a
cohort of patients with high C–reactive protein (CRP) levels despite achieving blood lipid control,
as measured by high sensitivity C-Reactive Protein (hsCRP) (3).
The final demonstration of atherosclerosis as an inflammatory-driven pathology is driving
research toward new anti-inflammatory approaches that could influence the natural history of the
disease and change the clinical paradigms of therapy. Considering the costs of canakinumab and
exploiting different avenues of anti-inflammatory therapies, a more affordable approach has been
proposed by the authors of the CANTOS study (4). Low dose methotrexate (MTX) proposed in
the CIRT study (5) could be an alternative approach aimed to lower the inflammatory burden and
to deliver a beneficial effect on patient CV risk (4). Data from this study is now available (5) and
demonstrates the feasibility of the lowMTX treatment and at the same time a somewhat surprising
lack of effect on CV risk.
In this published randomized trial low dose MTX did not reduce IL1-beta levels or hsCRP and
did not have any meaningful effect on cardiovascular disease (CVD) risk (a slight increase in skin
tumors was registered over time in the MTX treated population).
These results, while disappointing, are not entirely unexpected: MTX activity and the molecular
pathways involved are different from the canakinumab mechanism(s) of action, targeting less
relevant pathogenic signal cascades in atherosclerosis. Of note the CIRT trial was to a large extent
based on the data from patients affected by Rheumatoid Arthritis (RA) on low dose MTX in whom
(as observed) was shown to decrease both CV risk and inflammatory cytokine levels (4, 6–8). The
genesis of atherosclerotic lesions in RA remains an open and unsolved line of enquiry for further
research: Is atheromata driven by the same mechanism as classical atherosclerosis or is there a
disparate molecular pathway hidden among the CV framework? Maybe a greater extent of T cell
involvement could be a possible cause but only further research and observation will deliver the
dataset required. There is indeed mounting evidence that T cell subpopulations are involved in
the pathogenesis of atherosclerosis (9). Thus, in principle, we should be cautious in comparing the
results of the two trials without considering the differences in pathways and biological response.
This caveat notwithstanding, what are the hallmarks that we could extrapolate from this
nevertheless very interesting study?
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The first consideration is related to the target population of
each study (CANTOS and CIRT): as highlighted by the authors
(5) both trials involved heavily pre-treated subjects and prior
randomization, but the two populations used for CANTOS and
the CIRT study were actually different and not superimposable.
CANTOS included patients after myocardial infarction (MI)
with residual inflammatory risk as measured by hsCRP levels
higher than 2 mg/L despite aggressive therapy. CIRT had
patients with indirect evidence of inflammatory risk (not defined
by hsCRP levels) determined by the presence of diabetes
or metabolic syndrome (pathologies associated with a pro-
inflammatory pabulum). Levels of hsCRP were 4.2 mg/L as a
median baseline in CANTOS, whereas the median hsCRP level
was 1.6 mg/L at randomization in the CIRT population (3, 5).
Thus, in the CANTOS trial the pro-inflammatory pabulum
was definitely more pronounced (as per hsCRP levels) and
this situation could in part explain the different results of the
two studies.
Although both trials studied a high risk population, the event
rates for the same primary endpoint, a composite of non-fatal
MI, non-fatal stroke and CV death were considerably higher in
CANTOS (4.5/100 person years) compared with CIRT (3.43/100
person years). As an interesting point of fact, CIRT event rates
were at the level of those patients achieving an hsCRP < 2mg/L
with canakinumab in CANTOS (3.28/100 person years). Median
hsCRP levels in CIRT were indeed lower than in the CANTOS
placebo arm (as reported above).
Regarding MTX mechanisms of action, it has been reported
that MTX decreases elevated CV risk in patients with RA,
along with suppression of elevated CRP levels [CRP being less
sensitive and precise than hsCRP; (6, 7)]. So, it seems that
the inflammatory burden in the overall CIRT study population
may not have exceeded a certain threshold to benefit from
anti-inflammatory therapies, thus a positive role of MTX in
vascular wall disease is not entirely ruled out (6–8). These
assumptions are highlighted by the fact that we do not really
know the exact mechanism of action with low dose MTX
(10): the most stringent experimental proof is an increase
in adenosine (an important anti-inflammatory mediator) and
adenosine-related metabolite levels in treated patients (10) and
other possible mechanisms of action are proposed (10). At
this time, it is not known if the proposed mechanism(s) of
action of low dose MTX are relevant or scarcely relevant to
the pathogenesis of atherosclerosis or relevant only in some
stages of the disease. More studies focusing on the role of T
lymphocytes and adaptive immunity (9) in the natural history
and pathogenesis of atherosclerosis are warranted to better
understand the molecular action(s) and the eventual role of low
dose MTX.
A secondary and important aspect is that targeted inhibition
of inflammatory pathways is warranted in the case of
atherosclerosis for a significant therapeutic effect.
It is worth noting that in the CANTOS trial a definitive
reduction in Interleukin-6 (IL6) and hsCRP levels (known
inflammatory biomarkers downstream to IL1-beta signaling
pathway) were substantial, whereas no changes were registered
in the CIRT study.
It is conceivable that robust reduction of CV risk is
dependent on the specific pathways targeted. Of note, recent
experimental results on the involvement of the NLRP3 pathway
(a main trigger of IL1-beta release) seems to confirm the
pivotal role of specific signaling pro-inflammatory routes
in atherosclerosis pathophysiology (11–13). NLRP3 pathway
inhibition could indeed effectively target inflammatory pathways
in atherosclerosis (11–13). In this scenario it is interesting to
report the recent Novartis withdrawal of EU filing for approval
of canakinumab for CV risk reduction; the FDA had rejected
their application for the US market as well1. According to the
available reports the regulatory agencies were still concerned
that the beneficial effects might not outweigh the increased
risk of serious infections [see also (14–16)]. This is noteworthy
since canakinumab did reduce the overall CV mortality rate
by about 30% in patients that responded with a reduction in
hsCRP and IL6 after the first injection. “Non-responders” could
conveniently be identified by one follow-up hsCRPmeasurement
at 3 months and treatment could be terminated in these patients
sparing them the risk of experiencing serious side effects. In
“responders (hsCRP < 2 mg/L)” the benefits obviously outweigh
the risks resulting in an astonishing NNT (Number–Needed to
Treat) of 16! Based on this data we are of the opinion that
the research community needs to scrutinize the decisions being
made by the regulatory authorities (under exclusion of the public)
across the scientific literature; as this research sparks further
critical discussions, so too will other reviews cause different
interpretations of the data. Other specialists in the field of
Internal Medicine (such as rheumatologists) are used to suppress
the immune system to alleviate rheumatic and autoimmune
disease burden while balancing the risk for infections. There
is no reason to believe that cardiologists would not be able
to make comparable judgements based on that data. Thus, the
risk of serious adverse infectious effects related to canakinumab
use is clear, but we think that it could be manageable with
careful patient selection (i.e., excluding in future studies patients
with diabetes mellitus), and with a multi-specialist approach
to CV patients with a residual inflammatory “pabulum.” New
approaches (such as the NLRP3 inhibition mentioned above)
may be a possible solution in delivering therapeutic specificity
and efficacy while protecting patients from serious adverse
side effects.
In conclusion, we have to be grateful for the authors of
the CANTOS and CIRT studies who both delivered important
information to the medical community in regards to the
pathogenic mechanisms of atherosclerosis and its potential
clinical translations. Understanding differences and caveats in
the CANTOS, CIRT, and other studies involving additional
1http://www.pmlive.com/pharma_news/novartis_withdraws_eu_filing_for_
canakinumab_1272895 (accessed April 2, 2019);
https://www.epgonline.org/global/news/novartis-withdraws-from-ema-its-
application-for-canakinumab-for-the-prevention-of-serious-cv-events-.html
(accessed April 2, 2019);
https://endpts.com/fda-slaps-down-novartis-blockbuster-pitch-for-
canakinumab-so-what-went-wrong/ (accessed April 2, 2019);
https://business.medicaldialogues.in/fda-snubs-novartis-bid-to-repurpose-
inflammation-drug-canakinumab-for-heart-attacks/ (accessed April 2, 2019).
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anti-inflammatory therapies for CVD (14–20) is likely to be
useful in designing future therapeutics for atherosclerosis.
Critically, more studies are needed and it is not yet time for a
robust clinical application of these findings, but the CANTOS
and CIRT trials have paved the way for new personalized and
promising avenues for controlling this still devastating disease.
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